← All countries · Americas
91%
MCV1
2025 · WHO/UNICEF estimate
85%
DTP3
2025 · WHO/UNICEF estimate
93%
IPV complete
2025 · WHO/UNICEF estimate
85%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | —% · Administrative (country-reported) | — | too few points | no data |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | 99.2% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 85%2025 · WHO/UNICEF estimate | 84.9% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | 99.2% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 93%2025 · WHO/UNICEF estimate | 92.9% | C · weak | |
| MCV1First dose of measles-containing vaccine | 91%2025 · WHO/UNICEF estimate | 90.5% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 65%2025 · WHO/UNICEF estimate | 64.8% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 91%2025 · WHO/UNICEF estimate | 90.5% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 85%2025 · WHO/UNICEF estimate | 84.9% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 85%2025 · WHO/UNICEF estimate | 84.9% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 99.2%2025 · Administrative (country-reported) | 99.2% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 85%2025 · WHO/UNICEF estimate | 84.9% | A · strong | |
| RotaCRotavirus vaccine, complete series | 85%2025 · WHO/UNICEF estimate | 85.4% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | D · poor |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 100%2024 · WHO/UNICEF estimate | 92.3% | B · good | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 33%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 7%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 30%2025 · WHO/UNICEF estimate | — | B · good |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02019 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (49 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older with chronic conditions, other groups | |
| DTWPDTwP (Whole cell) vaccine | 5 | Y4-Y5 | General/routine | Children age 4 to 5 years |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | Infants and toddlers |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | Infants and toddlers |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | Infants and toddlers |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 4 | M15 | General/routine | Infants and toddlers |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | 1st contact | Travellers | Persons travelling to countries where Hepatitis A is endemic |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 2 | +M6 | Travellers | Persons travelling to countries where Hepatitis A is endemic |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | 1st contact | Adults | Adults 18 years & older |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Adults | Adults 18 years & older |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M5 | Adults | Adults 18 years & older |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9-Y12 | HPV administered to females and males | 1st contact to children aged 9 - 12 years |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M6 | HPV administered to females and males | 1st contact to children aged 9 - 12 years |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | Infants |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | Infants |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Y16 | General/routine | 1st contact at approximately age 16 years: students attending international colleges/universities |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Children 12 - 18 months |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M15 | General/routine | Children 12 - 18 months |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Health workers | High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox |
| MPOXMpox (monkeypox) vaccine | 1 | 1st contact | Risk group(s) | High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox |
| MPOXMpox (monkeypox) vaccine | 2 | +W4 | Health workers | High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox |
| MPOXMpox (monkeypox) vaccine | 2 | +W4 | Risk group(s) | High risk population including those who are sex workers, men who sex with men and healthcare workers, persons in contact with a suspected/confirmed case case of monkeypox |
| OPVOPV (Oral polio vaccine) | 3 | M6 | General/routine | Infants and preschoolers |
| OPVOPV (Oral polio vaccine) | 4 | Y4-Y5 | General/routine | Infants and preschoolers |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | Infants and toddlers |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | Infants and toddlers |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M6 | General/routine | Infants and toddlers |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 4 | M15 | General/routine | Infants and toddlers |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | 1st contact | Adults | Adults 50years and older with chronic conditions; children with sickle cell disease and elderly clients 65 years and older |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | 1st contact | Risk group(s) | Adults 50years and older with chronic conditions; children with sickle cell disease and elderly clients 65 years and older |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | infants |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | infants |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Antenatal women | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y10-Y12 | General/routine | Adolescents and adults |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Adults | Children and adults every 10 years | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | >Y10 | General/routine | Children 10 years and older |
| VARICELLAVaricella vaccine | 1 | M12 | General/routine | Children ages 1-5 |
| VARICELLAVaricella vaccine | 2 | Y4-Y5 | General/routine | Children ages 1-5 |
| YFYF (Yellow fever) vaccine | 1 | 1st contact | Travellers | Persons travelling to countries where yellow fever is endemic |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.